2-(氯甲基)-6-甲基吡啶盐酸盐 | 3099-30-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(氯甲基)-6-甲基吡啶盐酸盐
• 中文别名: 2-氯甲基-2-甲基吡啶盐酸盐；2-甲基-6-氯甲基吡啶盐酸盐
• 英文名称: 2-chloromethyl-6-methylpyridine hydrochloride
• 英文别名: 6-methyl-(2-chloromethyl)pyridine hydrochloride；2-(chloromethyl)-6-methylpyridine monohydrochloride；2-(chloromethyl)-6-methylpyridine;hydron;chloride
• CAS: 3099-30-7
• 化学式: C₇H₈ClN*ClH
• mdl: MFCD01691969
• 分子量: 178.061
• InChiKey: QFLPSIUFCCCRMI-UHFFFAOYSA-N

物化性质

• 熔点：
  146-153 °C(Solv: acetone (67-64-1))

计算性质

• 辛醇/水分配系数(LogP)：
  1.56
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  12.9
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Chloromethyl)-6-methylpyridine, HCl, tech grade
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Chloromethyl)-6-methylpyridine, HCl, tech grade
CAS number: 3099-30-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9Cl2N
Molecular weight: 178.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(氯甲基)-6-甲基吡啶盐酸盐 在 sodium hydroxide 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 、 乙醇 为溶剂， 生成 2-(6-methylpyrid-2-yl)tetrahydrothiophene
  参考文献：
  名称：

  Synthesis and antisecretory and antiulcer activities of derivatives and analogs of 2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide

  摘要：

  New thioamide derivatives of 2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide (29) and related compounds (in which the tetrahydrothiophene ring was replaced by tetrahydrothiopyran, tetrahydrofuran, 1,3-dithiane, or 1,3-oxathiane and where the pyridine ring was replaced by other nitrogen heterocycles) were synthesized and tested for their antisecretory and antiulcer activities. These thioamides were prepared according to one of the following methods: reaction of an isothiocyanate with the carbanion of the corresponding cyclic precursor (for secondary thioamides); reaction of ammonia or an amine with the dithio ester prepared from the same precursor (for primary, secondary, and tertiary thioamides). These thioamides were evaluated by the Shay method to measure their antisecretory activity and by the stress-induced-ulcer method to test their antiulcer activity. Structure-activity relationships are discussed. N-Methyl-2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide (R.P. 40749, 30) exhibited activities that were at least 10 times higher than those reported for cimetidine.

  DOI：

  10.1021/jm00384a004
• 作为产物：
  描述：

  6-methyl-2-pyridylcarbinol hydrochloride 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 以99%的产率得到2-(氯甲基)-6-甲基吡啶盐酸盐
  参考文献：
  名称：

  一系列新的配位不饱和硫醇盐-连接锰 (II) 配合物的表征和双氧反应性

  摘要：

  四种新型配位不饱和单核硫醇连接锰 (II) 配合物 ([Mn II (S Me2 N 4 (6-Me-DPEN))](BF 4 ) ( 1 ), [Mn II (S Me2 N 4 (6-Me-DPPN))](BPh 4 )·MeCN ( 3 ), [Mn II (S Me2 N 4 (2-QuinoPN))](PF 6 )·MeCN·Et 2 O ( 4 ) 和 [Mn II (S Me2 N 4 (6-H-DPEN)(MeOH)](BPh 4 ) (5 )) 以及它们的磁性、氧化还原和反应性特性。这些复合物在结构上与最近报道的 [Mn II (S Me2 N 4 (2-QuinoEN))](PF 6 ) ( 2 ) (Coggins, MK; Kovacs, JA J. Am. Chem. Soc. 2011 , 133 , 12470）。复合物1 – 5的双氧加成导致形成五个新的稀有实例

  DOI：

  10.1021/ic300192q
• 作为试剂：
  描述：

  6-甲基-2-吡啶基甲醇 、 氯化亚砜 在 氯化亚砜 、 2-(氯甲基)-6-甲基吡啶盐酸盐 作用下， 反应 18.0h， 生成 2-(氯甲基)-6-甲基吡啶盐酸盐
  参考文献：
  名称：

  Imidazole derivatives

  摘要：

  本发明涉及式I的咪唑衍生物，其中R1、R2、R3、R4、X、Y和R如上所述，或其药学上可接受的盐。本发明还涉及包含式I的咪唑衍生物的制药组合物，制备式I化合物的方法，以及治疗或预防急性和/或慢性神经系统疾病的方法，包括向需要此类治疗和/或预防的患者施用所述制药组合物的治疗有效量。这些疾病包括阿尔茨海默病，也包括轻度认知障碍。

  公开号：

  US07452909B2

文献信息

• Substituted thiazolyl and substituted pyridinyl derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05360807A1

  公开（公告）日：1994-11-01

  Substituted thiazolyl and substituted pyridinyl derivatives of formula ##STR1## the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein --A.sup.1 .dbd.A.sup.2 --A.sup.3 .dbd.A.sup.4 -- is a bivalent radical having the formula --CH.dbd.CH--CH.dbd.CH-- (a-1), --N.dbd.CH--CH.dbd.CH-- (a-2), --CH.dbd.N--CH.dbd.CH-- (a-3), --CH.dbd.CH--N.dbd.CH-- (a-4), --CH.dbd.CH--CH.dbd.N-- (a-5), --N.dbd.CH--N.dbd.CH-- (a-6) or --CH.dbd.N--CH.dbd.N-- (a-7); B represents NR.sup.1, CH.sub.2, O, S, SO or SO.sub.2 wherein R.sup.1 is hydrogen or C.sub.1-4 -alkyl; R is a radical of formula; ##STR2## wherein D is C.sub.1-4 alkanediyl; R.sup.2 is C.sub.1-6 alkyl; n is 0, 1 or 2; L is hydrogen; C.sub.1-12 alkyl; C.sub.3-6 cycloalkyl; C.sub.3-6 alkenyl optionally substituted with aryl; C.sub.1-6 alkylcarbonyl; C.sub.1-6 alkyloxycarbonyl; arylcarbonyl; arylC.sub.1-6 alkyloxycarbonyl; or a radical of formula --Alk--R.sup.3 (c- 1); --Alk--Y--R.sup.4 (c-2); --Alk--Z.sup.1 --C(.dbd.X)--Z.sup.2 --R.sup.5 (c-3); or --CH.sub.2 --CHOH--CH.sub.2 --O--R.sup.6 (c-4); have antiallergic properties. Compositions containing the same and methods of treating warm-blooded animals suffering from allergic diseases.

  公式##STR1##中的取代噻唑基和取代吡啶基衍生物，其药学上可接受的酸盐和立体化学异构体形式，其中--A.sup.1 .dbd.A.sup.2 --A.sup.3 .dbd.A.sup.4 --是具有--CH.dbd.CH--CH.dbd.CH--（a-1），--N.dbd.CH--CH.dbd.CH--（a-2），--CH.dbd.N--CH.dbd.CH--（a-3），--CH.dbd.CH--N.dbd.CH--（a-4），--CH.dbd.CH--CH.dbd.N--（a-5），--N.dbd.CH--N.dbd.CH--（a-6）或--CH.dbd.N--CH.dbd.N--（a-7）的分子式的二价基团；B代表NR.sup.1，CH.sub.2，O，S，SO或SO.sub.2，其中R.sup.1是氢或C.sub.1-4-烷基；R是具有分子式的基团；##STR2##其中D是C.sub.1-4烷二基；R.sup.2是C.sub.1-6烷基；n为0、1或2；L为氢；C.sub.1-12烷基；C.sub.3-6环烷基；C.sub.3-6烯基，可选择地取代芳基；C.sub.1-6烷基羰基；C.sub.1-6烷氧羰基；芳基羰基；芳基C.sub.1-6烷氧羰基；或具有分子式的基团--Alk--R.sup.3（c-1）；--Alk--Y--R.sup.4（c-2）；--Alk--Z.sup.1--C(.dbd.X)--Z.sup.2--R.sup.5（c-3）；或--CH.sub.2--CHOH--CH.sub.2--O--R.sup.6（c-4）；具有抗过敏性能。含有这些物质的组合物以及治疗患有过敏性疾病的温血动物的方法。
• Facial triad modelling using ferrous pyridinyl prolinate complexes: synthesis and catalytic applications
  作者：Marcel A. H. Moelands、Daniel J. Schamhart、Emma Folkertsma、Martin Lutz、Anthony L. Spek、Robertus J. M. Klein Gebbink

  DOI：10.1039/c3dt53266f

  日期：——

  conditions (coordinating or non-coordinating solvents) and the presence of substituents on the ligand. In combination with Fe(II)(OTf)2, coordinatively saturated complexes of the type [Fe(L)2](OTf)2 are formed, in which the ligands adopt a meridional coordination mode. The use of FeCl2 in a non-coordinating solvent leads to 5-coordinated complexes [Fe(L)(Cl)2] with a meridional N,N′,O ligand. Crystallization

  据报道一系列新的手性吡啶基脯氨酸吡啶酸酯（RPyProR）配体及其相应的三氟甲磺酸铁（II）和氯化物络合物。配体具有NN'O配位基序，这是在非血红素铁酶与所谓的2-His-1-羧化物面部三联征的活性位点中发现的。这些配体对铁的配位行为证明取决于抗衡离子（氯离子或三氟甲磺酸根），结晶条件（配位或非配位溶剂）以及配位体上取代基的存在。与Fe（II）（OTf）2结合，形成[Fe（L）2 ]（OTf）2类型的配位饱和配合物形成其中配体采用子午配位模式。在非配位溶剂中使用FeCl 2会生成具有子午线N，N'，O配体的5位配位配合物[Fe（L）（Cl）2 ]。这些配位化合物从配位溶剂中结晶会生成6位配位的[Fe（L）（solv）（Cl）2 ]配位化合物（solv =甲醇或乙腈），其中N，N'，O配体在面部被配位方式。对于RPyProR吡啶环上带有6-Me取代基的配体，溶剂配位以及相应的配体重排可通过空
• Amine-Linked Flavonoids as Agents against Cutaneous Leishmaniasis
  作者：Chin-Fung Chan、Zhen Liu、Iris L. K. Wong、Xianliang Zhao、Zaofeng Yang、Jiale Zheng、Marianne M. Lee、Michael K. Chan、Tak Hang Chan、Larry M. C. Chow

  DOI：10.1128/aac.02165-20

  日期：2021.4.19

  We have designed, synthesized, and characterized a library of 38 novel flavonoid compounds linked with amines. Some of these amine-linked flavonoids have potent in vitro activity against parasites that cause cutaneous leishmaniasis, a tropical disease endemic in 80 countries worldwide.

  我们设计、合成并鉴定了一个由 38 种与胺相连的新型类黄酮化合物组成的化合物库。其中一些与胺相连的黄酮类化合物具有强效的 体外 对引起皮肤利什曼病（一种在全球 80 个国家流行的热带疾病）的寄生虫有很强的体外活性。
• Efficient and Selective Peracetic Acid Epoxidation Catalyzed by a Robust Manganese Catalyst
  作者：Isaac Garcia-Bosch、Anna Company、Xavier Fontrodona、Xavi Ribas、Miquel Costas

  DOI：10.1021/ol800329m

  日期：2008.6.5

  catalyst containing a tetradentate ligand derived from triazacyclononane exhibits high catalytic activity in epoxidation reactions using peracetic acid as oxidant. The system exhibits broad substrate scope and requires small (0.1-0.15 mol %) catalyst loading. The catalyst is remarkably selective toward aliphatic cis-olefins. Mechanistic studies point toward an electrophilic oxidant delivering the oxygen

  含有衍生自三氮杂环壬烷的四齿配体的锰催化剂在使用过氧乙酸作为氧化剂的环氧化反应中表现出高催化活性。该系统具有广泛的底物范围，并且需要少量（0.1-0.15 mol％）的催化剂负载量。该催化剂对脂族顺式烯烃具有显着的选择性。机理研究表明，亲电子氧化剂可以协同地传递氧原子。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson H. John

  公开号：US20070105866A1

  公开（公告）日：2007-05-10

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本发明描述了调节5-脂氧合酶激活蛋白(FLAP)活性的化合物和含有该化合物的药物组合物。本发明还描述了单独使用和与其他化合物联合使用FLAP调节剂，用于治疗呼吸系统、心血管系统和其他白三烯依赖性或白三烯介导的状况或疾病。